首页> 外文期刊>癌症生物学与医学(英文版 ) >Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients
【24h】

Bcl-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andropause-age patients

机译:Bcl-2表达不能预测更年期患者的肝细胞癌预后

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: The expression of B-cell lymphoma 2 (Bcl-2) seems to be influenced by the endocrine environment. Numerous reports demonstrate the diverse expression of Bcl-2 family members under sex steroid regulation. With the exception of estrogen-related tumors, androgen-related tumors have shown their characteristics in Bcl-2 expression. In this study, the status of Bcl-2 expression in male hepatocellular carcinoma (HCC) patients was examined to verify the high incidence of HCC in males. Methods: Tumor tissue microarray was used to examine Bcl-2 expression levels in 374 HCC cases including 306 males and 68 females. Kaplan-Meier method, log-rank test, and Cox proportional hazards model were applied to investigate the predictive value of Bcl-2 in HCC patients. Results: Immunohistochemistry analysis showed that male patients with higher Bcl-2 levels had significantly longer median survival time and recurrence time than those with lower levels. However, no significant differences in outcomes were found between different Bcl-2 levels in female patients. When the male patients were stratified into several age points, the level of Bcl-2 expression showed poorer predictive efficiency in the 45–49 and 55–60 age groups in andropause-age patients compared with other age groups. Bcl-2 was an independent prognostic factor for both overall survival (P < 0.0001) and recurrence time (P =0.0001) in male patients. After excluding male patients in the 45–60 age group, the predictive efficiency was enhanced (n = 147, OS,P = 0.0002, TTR,P < 0.0001). Conclusions: Bcl-2 expression is an independent predictor of survival and recurrence in male HCC. Bcl-2 levels may also be regulated by androgens or androgen receptors in male HCC patients. Bcl-2 levels change and exhibit poor predictive efficiency when androgen levels vary dramatically (andropause age).
机译:目的:B细胞淋巴瘤2(Bcl-2)的表达似乎受内分泌环境的影响。许多报道表明在性类固醇调节下Bcl-2家族成员的多样化表达。除了与雌激素有关的肿瘤外,与雄激素有关的肿瘤在Bcl-2表达中也显示出它们的特征。在这项研究中,检查Bcl-2在男性肝细胞癌(HCC)患者中的表达状态,以验证男性HCC的高发率。方法:采用肿瘤组织微阵列技术检测374例HCC患者中Bcl-2表达水平,其中男306例,女68例。应用Kaplan-Meier法,log-rank检验和Cox比例风险模型研究Bcl-2在肝癌患者中的预测价值。结果:免疫组织化学分析显示,Bcl-2水平较高的男性患者的中位生存时间和复发时间明显低于Bcl-2水平较低的男性。但是,在女性患者中,不同Bcl-2水平之间的转归没有显着差异。当男性患者分为多个年龄点时,与其他年龄组相比,男性更年期患者在45–49和55–60年龄组中Bcl-2表达水平显示较差的预测效率。 Bcl-2是男性患者总生存期(P <0.0001)和复发时间(P = 0.0001)的独立预后因素。在排除了45-60岁年龄段的男性患者后,预测效率得到了增强(n = 147,OS,P = 0.0002,TTR,P <0.0001)。结论:Bcl-2表达是男性肝癌生存和复发的独立预测因子。在男性HCC患者中,Bcl-2水平也可能受雄激素或雄激素受体的调节。当雄激素水平发生巨大变化时(成年年龄),Bcl-2水平会发生变化并显示出较差的预测效率。

著录项

  • 来源
    《癌症生物学与医学(英文版 )》 |2016年第4期|459-468|共10页
  • 作者单位

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Qidong Hospital, Qidong 226200, China;

    Department of General Surgery, Qidong Hospital, Qidong 226200, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

    Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号